These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17451359)

  • 1. Effectiveness of a mycoplasma elimination reagent on a mycoplasma-contaminated hybridoma cell line.
    Kumar A; Ali A; Yerneni LK
    Hybridoma (Larchmt); 2007 Apr; 26(2):104-6. PubMed ID: 17451359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The elimination of mycoplasma from infected hybridomas by passaging in BALB/c mice.
    Carroll K; O'Kennedy R
    J Immunol Methods; 1988 Apr; 108(1-2):189-93. PubMed ID: 2450926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimycoplasma properties and application in cell culture of surfactin, a lipopeptide antibiotic from Bacillus subtilis.
    Vollenbroich D; Pauli G; Ozel M; Vater J
    Appl Environ Microbiol; 1997 Jan; 63(1):44-9. PubMed ID: 8979337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of three methods for curing hybridomas from mycoplasma contamination.
    Ravaoarinoro M; Lecomte J
    Hybridoma; 1988 Feb; 7(1):79-86. PubMed ID: 2453449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective treatment of mycoplasma contamination in cell lines with enrofloxacin (Baytril).
    Fleckenstein E; Uphoff CC; Drexler HG
    Leukemia; 1994 Aug; 8(8):1424-34. PubMed ID: 7520103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of mycoplasma contaminations.
    Uphoff CC; Drexler HG
    Methods Mol Biol; 2013; 946():15-26. PubMed ID: 23179823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curing human hybridomas infected with Mycoplasma hyorhinis.
    Borup-Christensen P; Erb K; Jensenius JC
    J Immunol Methods; 1988 Jun; 110(2):237-40. PubMed ID: 3379313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of mycoplasmas from infected cell lines using antibiotics.
    Uphoff CC; Drexler HG
    Methods Mol Biol; 2011; 731():105-14. PubMed ID: 21516401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibilities of Mycoplasma fermentans and Mycoplasma hyorhinis to membrane-active peptides and enrofloxacin in human tissue cell cultures.
    Nir-Paz R; Prévost MC; Nicolas P; Blanchard A; Wróblewski H
    Antimicrob Agents Chemother; 2002 May; 46(5):1218-25. PubMed ID: 11959548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lipopeptides mycosubtilin and surfactin enhance spreading of Bacillus subtilis strains by their surface-active properties.
    Leclère V; Marti R; Béchet M; Fickers P; Jacques P
    Arch Microbiol; 2006 Dec; 186(6):475-83. PubMed ID: 16964493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic sensitivities and elimination of mycoplasmas from infected cell cultures.
    Gardella RS; Del Giudice RA
    Isr J Med Sci; 1984 Oct; 20(10):931-4. PubMed ID: 6511319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of lipopolysaccharide activity by a bacterial cyclic lipopeptide surfactin.
    Takahashi T; Ohno O; Ikeda Y; Sawa R; Homma Y; Igarashi M; Umezawa K
    J Antibiot (Tokyo); 2006 Jan; 59(1):35-43. PubMed ID: 16568717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mycoplasma infection as a possible cause of hybridoma instability].
    Volgareva GM; Neustroeva VV; Sviridov VV
    Mol Gen Mikrobiol Virusol; 1985 Jan; (1):34-8. PubMed ID: 3879880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safe and efficient method for elimination of cell culture mycoplasmas using ciprofloxacin.
    Schmitt K; Däubener W; Bitter-Suermann D; Hadding U
    J Immunol Methods; 1988 Apr; 109(1):17-25. PubMed ID: 3282011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and characterization of microbial biosurfactants for potential use in oil-spill remediation.
    Marti ME; Colonna WJ; Patra P; Zhang H; Green C; Reznik G; Pynn M; Jarrell K; Nyman JA; Somasundaran P; Glatz CE; Lamsal BP
    Enzyme Microb Technol; 2014 Feb; 55():31-9. PubMed ID: 24411443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of mycoplasma from leukemia-lymphoma cell lines using antibiotics.
    Uphoff CC; Meyer C; Drexler HG
    Leukemia; 2002 Feb; 16(2):284-8. PubMed ID: 11840296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of mycoplasma-contaminated continuous cell lines with mycoplasma removal agent (MRA).
    Gignac SM; Uphoff CC; MacLeod RA; Steube K; Voges M; Drexler HG
    Leuk Res; 1992 Aug; 16(8):815-22. PubMed ID: 1326687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of mycoplasma contamination in cell cultures with Plasmocin.
    Uphoff CC; Denkmann SA; Drexler HG
    J Biomed Biotechnol; 2012; 2012():267678. PubMed ID: 23091342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A "lymphokine-like" soluble product that induces proliferation and maturation of B cells appears in the serum-free supernatant of a T cell hybridoma as a consequence of mycoplasmal contamination.
    Proust JJ; Buchholz MA; Nordin AA
    J Immunol; 1985 Jan; 134(1):390-6. PubMed ID: 3871110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of mycoplasma from infected leukemia cell lines.
    Gignac SM; Brauer S; Häne B; Quentmeier H; Drexler HG
    Leukemia; 1991 Feb; 5(2):162-5. PubMed ID: 2020199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.